Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
-
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
-
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23,...
-
SAN FRANCISCO, July 17, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
-
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
-
SAN FRANCISCO, July 07, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May...
-
SAN FRANCISCO, July 02, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Class Period: May 23, 2022...
-
SAN FRANCISCO, May 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Visit:...
-
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”)...
-
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ: IBRX) investors who suffered substantial losses to submit your losses now. Visit:...